Cell therapy system

• US 20030175242A1
• Filed: 09/17/2002
• Published: 09/18/2003
• Est. Priority Date: 09/17/2001
• Status: Abandoned Application

• Current Assignee: Medcell Biologics, LLC
• Original Assignee: Medcell Biologics, LLC
• Inventors: Gruenberg, Micheal
• Application Number:
  US10/246,293
• Publication Number:
  US 20030175242A1
• Time in Patent Office: Days
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2035/122 for inducing tolerance or supression of immune responses
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/26 Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: C12N 2501/51 B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
• CPC Class Codes: C12N 2501/515 CD3, T-cell receptor complex
• CPC Class Codes: C12N 5/0636 T lymphocytes
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 40/67 for remote operation

Abstract

Systems and methods for manufacturing and distributing somatic cell therapy and gene therapy products are provided. The systems and methods include establishing a central processing facility and a plurality of satellite facilities administered under a single government license for conducting somatic cell or gene therapy, collecting source material at one of the satellite facilities from a first subject, transporting the source material from the first subject and delivering the source material to the central processing facility, processing the source material from the first subject at the central processing facility to produce a therapy product for administration to the same first subject, transporting the therapy product back to the satellite facility and administering the therapy product to the same first subject. All steps are performed under the control of the manufacturer.

Claims

1. A therapy method, comprising:

a) establishing a central processing facility and a plurality of satellite facilities for conducting somatic cell or gene therapy;

b) collecting source biological material at one of the satellite facilities from a first subject;

c) transporting the source material from the first subject and delivering the source material to the central processing facility;

d) processing the source material from the first subject at the central processing facility to produce a therapy product; and

e) transporting the therapy product back to the satellite facility for administration to a subject, wherein all steps are performed, such that the manufacturer has vein-to-vein control over the processes, facilities and products, and source material is tracked from collection through processing to infusion of the product derived from the source material.

2. The method of claim 1, wherein all steps are performed under the control of one manufacturer, which controls personnel, facilities, equipment, documentation and procedures used at the collection and administration of somatic cell and gene therapy products.

3. The method of claim 1, wherein all steps are performed under a single government license.

4. The method of claim 1, wherein each of the plurality of satellite facilities are located in distinctly separate subject locations.

5. The method of claim 1, further comprising establishing at least one more additional central processing facility.

6. The method of claim 1 wherein the therapy product is an autologous product.

7. The method of claim 1, wherein the satellite facilities are connected to the central processing facility through a global computer network in which data specific to the first subject is collected, transmitted and stored for use for processing the source material and for administering the therapy product back to the first subject.

8. The method of claim 4, further comprising:

labeling source material collected for shipment to the central processing facility; and

transporting the therapy product made from the source material back to the satellite facility for administration to the first subject with an identifying symbology.

9. The method of claim 8, wherein the symbology is an optically readable label.

10. The method of claim 8, wherein the label identifies the subject from whom the material was obtained.

11. The method of claim 7, further comprising:

creating a digital photograph of the first subject to ensure positive subject identification and association with the source material collected and for positive identification and association for administering the resulting therapy product to the same first subject.

12. The method of claim 1, wherein:

source material is collected from a plurality of subject;

the first subject is one of a plurality of subjects at each of the satellite facilities;

the source material is transported to the central processing facility to produce therapy products specific to each of the plurality of subjects derived from source material obtained from such subjects; and

transporting each of the therapy products back to the satellite facility from which the source material was obtained and administering the therapy product to the same subject from which the source material was obtained.

13. The method of claim 8, wherein the satellite facilities are connected to the central processing facility through a global computer network in which data for each subject from which source material is collected is entered, associated with the source material, and stored for use for processing the source material, and then used for transporting back the therapy product produced from the source material for each subject and for administering the therapy product back to the subject from which the original source material that produced the specific therapy product was obtained.

14. The method of claim 1, wherein processing in step d) is effected by a method, comprising:

i) purifying T-cells from the source material; and

ii) activating the T-cells a minimum of 3 times at 2-4 day intervals, whereby a highly pure population of polyclonal Th1 memory cells is produced.

15. The method of claim 14, wherein the T-cells are purified CD4+ cells.

16. The method of claim 14, wherein the CD4+ cells are purified by positive selection

17. The method of claim 16 wherein the CD4+ cells are purged of CD45RO+ cells

18. The method of claim 14, wherein the source material is purged of platelets

19. The method of claim 17, wherein the source material is purged of platelets

20. The method of claim 14, wherein the source material is purged of monocytes.

21. The method of claim 19, wherein the source material is purged of monocytes.

22. The method of claim 14, wherein the activation of T-cells is effected by contacting the cells by contacting with anti-CD3 and anti-CD28 monoclonal antibodies (mAbs).

23. The method of claim 22, wherein the anti-CD3 and anti-CD28 mAbs are immobilized.

24. The method of claim 22, wherein the anti-CD3 and anti-CD28 mAbs are immobilized on particles.

25. The method of claim 24, wherein the particles are initially administered to the purified T-cells at a 3:

1 particle;

cell ratio and, in subsequent steps, at a 1;

1 particle;

cell ratio.

26. The method of claim 1, wherein the subject has a disease characterized by either an excess of Th2 cytokine activity or low Th1 cytokine activity.

27. The method of claim 1, wherein the subject has a disease selected from the group consisting of diseases characterized by suppression of the cellular immune response or by over-expression of the humoral immune response.

28. The method of claim 1, wherein the subject has a disease selected from the group consisting of cancer, infectious diseases, autoimmune and allergic diseases.

29. The method of claim 14, wherein the subject has a disease selected from the group consisting of diseases characterized by suppression of the cellular immune response or by over-expression of the humoral immune response.

30. The method of claim 14, wherein the subject has disease selected from the group consisting of cancer, infectious diseases, autoimmune and allergic diseases.

31. The method of claim 1, wherein processing at step d) is effected by a method, comprising:

(i) reducing the number of platelets in the sample;

(ii) purging macrophages from the sample;

(iii) purging the CD45RO + cells from the sample

(iv) purifying by positive selection a population of CD4+, CD45RA+ cells;

(v) activating the CD4+ cells in the absence of exogenous cytokines with immobilized anti-CD3/anti-CD28 mAb; and

(vi) periodically restimulating with immobilized anti-CD3/anti-CD28 mAb.

32. The method of claim 31, wherein, at step (vi), the cells are restimulated every 2-3 days with immobilized anti-CD3/anti-CD28 mAb for a total of 10-14 days.

33. The method of claim 31, wherein, after transporting the cells to the satellite facility, the cells from the resulting cell therapy product containing Th1 memory cells are infused into the subject, thereby altering the Th1/Th2 cell balance of the subject.

34. The method of claim 14, wherein the resulting cell therapy product is transported to a satellite facility and then cells in the product are re-activated cells prior to infusion.

35. The method of claim 14, wherein the harvested cells are frozen, transported to satellite facility, thawed, and then reactivated prior to infusion.

36. The method of claim 34, wherein, the cells are re-activated no more than about 4 hours prior to infusion.

37. The method of claim 35, wherein, the cells are re-activated no more than about 4 hours prior to infusion.

38. The method of claim 34, wherein, prior to re-activating, the cells are rested for about 24 to about 120 hours, wherein resting includes time for transporting form a central processing facility to a satellite facility and or after transporting to a satellite facility.

39. The method of claim 38, wherein the cells are rested for about 72 to about 96 hours before reactivation.

40. The method of claim 38, wherein all or a portion of the resting period occurs after processing and during transporting the therapy product back to a satellite facility.

41. The method of claim 38, wherein all or a portion of the resting period occurs after processing and after transporting the therapy product back to the satellite facility.

42. The method of claim 34, wherein re-activation is effected by

contacting the cells with activating monoclonal antibodies;

and then

mixing them with peripheral blood monocytes.

43. The method of claim 34, wherein cells from the resulting cell therapy product are then infused into the patient from whom the source biological material was removed.

44. The method of claim 1, wherein the therapy product comprises purified CD4+ cells.

45. The method of claim 1, wherein the therapy product comprises T-cells suspended in plasma, wherein the plasma is autologous with respect to the T-cells.

46. The method of claim 1, wherein the therapy product comprises T-cells at a density of at least about 10⁷ T-cells per ml.

59. The method of claim 1, wherein the subject is a human.

60. The method of claim 1, further comprising:

infusing cells from the resulting cell therapy product into the subject from whom the source biological material was removed.

47. A cell therapy system that for production of a therapy product, comprising:

a plurality of satellite facilities, wherein each satellite facility collects a source material from a subject, administers the therapy product to the subject, or any combination of any of these; and

a central processing facility that is connected to each satellite facility, wherein the central processing facility processes the source material to form the therapy product, wherein;

a single manufacturer controls all satellite and central processing facilities; and

the cell therapy system is effective to collect source material from a subject, transform the source material into the autologous therapy product, and administer the therapy product to a subject.

48. The system of claim 47, wherein each satellite facility and the central processing facility operate under a single government license for conducting somatic cell therapy or gene therapy.

49. The system of claim 47, further comprising computer network connections between and among the central processing facility and each satellite facility.

50. The system of claim 49, wherein the network is a secure global computer network.

51. The system of claim 47, wherein each facility collects the source material, administers the therapy product or any combination of any of these.

52. The system of claim 47, wherein the central processing facility transforms the source material into the autologous therapy product.

53. The system of claim 47, further comprising means for tracking chain-of-custody of source material from collection to infusion.

61. The system of claim 53, wherein the means comprise an optical reading and writing system.

62. The system of claim 61, wherein the optical reading an writing system generates and reads bar codes.

63. The system of claim 47, further comprising documentation and protocols for performing obtaining source material for cell therapy and preparing cell therapy products under a single governmental license.

54. A method of producing an autologous somatic cell therapy product, comprising:

processing a subject at a satellite facility to identify and track the subject;

obtaining source material from the subject;

transforming a source material into the autologous somatic cell therapy product at a central processing facility connected to the satellite facility via a computer network,

wherein all steps are performed, such that the manufacturer has vein-to-vein control over the processes, facilities and products.

55. The method of claim 54, wherein the satellite facility is located at a separate facility from the central processing facility.

56. The method of claim 54, wherein the satellite facility and the central processing facility are administered under a single government license for conducing somatic cell therapy or gene therapy.

57. The method of claim 54, further comprising, transporting a cell therapy product from a central processing facility, wherein the transporting and tracking thereof are controlled by the manufacturer.

58. The method of claim 54, further comprising identifying the subject from whom the source material was obtained, and administering the cells to the subject.